We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
-10.52%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$314M
AUM Growth
-$86.9M
Cap. Flow
-$24.2M
Cap. Flow %
-7.71%
Top 10 Hldgs %
50.55%
Holding
86
New
32
Increased
12
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$18.5M
2
SRRK icon
Scholar Rock
SRRK
+$15.4M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$13.5M
4
QURE icon
uniQure
QURE
+$8.99M
5
CGON icon
CG Oncology
CGON
+$8.15M

Top Sells

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$18M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$16.2M
3
INCY icon
Incyte
INCY
+$13.4M
4
MRUS
Merus
MRUS
+$11.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SION
51
Sionna Therapeutics
SION
$2.23B
$628K 0.2%
+60,000
New +$980K
BCAX
52
Bicara Therapeutics
BCAX
$1.82B
$613K 0.2%
+47,078
New +$625K
EWTX icon
53
PUT
Edgewise Therapeutics
EWTX
$4.28B
$238K 0.08%
+50,000
New +$1.31M
CVS icon
54
PUT
CVS Health
CVS
$137B
$165K 0.05%
+64,100
New +$3.84M
MLYS icon
55
PUT
Mineralys Therapeutics
MLYS
$2.39B
$93.8K 0.03%
+125,000
New +$1.44M
ARQT icon
56
CALL
Arcutis Biotherapeutics
ARQT
$3.56B
$42.5K 0.01%
100,000
-1,475,000
-94% -$20.8M
KALV
57
CALL
DELISTED
KalVista Pharmaceuticals
KALV
$32.5K 0.01%
+100,000
New +$1.02M
BBC icon
58
CALL
Virtus Biotech Clinical Trials ETF
BBC
$53.5M
$16.6K 0.01%
+132,500
New +$2.84M
RYTM icon
59
CALL
Rhythm Pharmaceuticals
RYTM
$7.31B
$15.5K ﹤0.01%
+10,000
New +$555K
MRK icon
60
CALL
Merck
MRK
$315B
$8.34K ﹤0.01%
+151,700
New +$14.2M
NVO
61
CALL
Novo Nordisk
NVO
$223B
$3.79K ﹤0.01%
+151,700
New +$12.5M
BMY icon
62
Bristol-Myers Squibb
BMY
$124B
– –
-166,068
Closed -$9.39M
BNTX icon
63
BioNTech
BNTX
$23.1B
– –
-61,403
Closed -$7M
CDTX
64
DELISTED
Cidara Therapeutics
CDTX
– –
-47,642
Closed -$1.28M
CRNX icon
65
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-317,060
Closed -$16.2M
ETNB
66
DELISTED
89bio
ETNB
– –
-545,800
Closed -$4.27M
EYPT icon
67
EyePoint Inc
EYPT
$1.12B
– –
-579,500
Closed -$4.32M
HIMS icon
68
CALL
Hims & Hers Health
HIMS
$7.6B
– –
-75,000
Closed -$75K
INCY icon
69
Incyte
INCY
$23.4B
– –
-193,623
Closed -$13.4M
IOVA icon
70
Iovance Biotherapeutics
IOVA
$2.23B
– –
-949,401
Closed -$7.03M
JSPR icon
71
Jasper Therapeutics
JSPR
$29.4M
– –
-135,244
Closed -$2.89M
MLYS icon
72
Mineralys Therapeutics
MLYS
$2.39B
– –
-400,101
Closed -$4.6M
NMRA icon
73
Neumora Therapeutics
NMRA
$298M
– –
-428,137
Closed -$4.54M
PRAX icon
74
Praxis Precision Medicines
PRAX
$8.77B
– –
-134,178
Closed -$10.3M
QQQ icon
75
PUT
Invesco QQQ Trust
QQQ
$462B
– –
-70,000
Closed -$515K
1 2
3
4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Stempoint Capital held 86 positions worth $314M, down 22% from $401M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital withdrew a net $24.2M in Q1 2025, closing 25 positions and reducing 15 holdings. Its most notable exit was Crinetics Pharmaceuticals, an estimated $16.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Stempoint Capital opened a new position in Arcellx worth $18M.

  • Stempoint Capital's largest Q1 2025 buy was Arcellx: 273,774 shares worth $18M.
  • Stempoint Capital added most to Scholar Rock in Q1 2025, an estimated $15.4M increase.
  • Stempoint Capital's biggest Q1 2025 reduction was Syndax Pharmaceuticals, cutting an estimated $18M.
  • Stempoint Capital fully exited Crinetics Pharmaceuticals in Q1 2025, selling an estimated $16.2M.
  • Stempoint Capital's ten largest holdings make up 51% of its $314M portfolio in Q1 2025.
  • Stempoint Capital opened 32 new positions and closed 25 in Q1 2025.
  • Stempoint Capital's portfolio value fell 22% quarter-over-quarter to $314M.

Based on Stempoint Capital's 13F filing for Q1 2025, filed 15 May 2025.